Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses the largest prospective VHL disease-specific therapeutic trial performed to date, and the data that show pazopanib resulted in significant and sustained disease control for the majority of patients enrolled on the study. (Abstract 4516)
Elizabeth J. Shpall, MD, of The University of Texas MD Anderson Cancer Center, and recipient of the 2017 Women Who Conquer Cancer Mentorship Award, discusses promoting women in onc...
John Marshall, MD, of Georgetown University, and John Neil Primrose, PhD, MBBS, of the University of Southampton, discuss the potentially practice-changing finding...
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Clifford A. Hudis, MD, ASCO’s current CEO, discuss the state of cancer care and the challeng...
Ethan M. Basch, MD, of the University of North Carolina, discusses results from a study that assessed patient-reported outcomes for symptom monitoring during routine cancer treatme...
Xuesong Han, PhD, of the American Cancer Society, discusses the Affordable Care Act and her study findings showing how implementation of the law is associated with a shift to early...
